NCT05971693已完成不适用
Safety and Effectiveness Evaluation of the OMNYPULSE Catheter With the TRUPULSE Generator for Treatment of Paroxysmal Atrial Fibrillation (PAF)
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 188
- 试验地点
- 26
- 主要终点
- Percentage of Participants with Acute Effectiveness
研究概览
简要总结
The purpose of this study is to demonstrate safety and effectiveness of the ablation system (OMNYPULSE Bi-directional catheter and TRUPULSE generator) when used for isolation of the atrial pulmonary veins (PVs) in treatment of participants with paroxysmal atrial fibrillation (PAF).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosed with Symptomatic paroxysmal atrial fibrillation (PAF) defined as as atrial fibrillation (AF) that terminates spontaneously or with intervention within 7 days of onset. This PAF is considered to be symptomatic if symptoms related to AF are experienced by the participant
- •Selected for AF ablation procedure by pulmonary vein isolation (PVI)
- •Willing and capable of providing consent
- •Able and willing to comply with all pre-, post- and follow-up testing and requirements
排除标准
- •Previously known AF secondary to electrolyte imbalance, thyroid disease, or reversible or non-cardiac cause (example, documented obstructive sleep apnea, acute alcohol toxicity, morbid obesity [body mass index greater than {>} 40 kilograms per meter square {kg/m^2}]), renal insufficiency (with an estimated creatinine clearance less than (<) 30 milliliters per minute per 1.73 meter square [mL/min/1.73 m^2])
- •Previous left atrium (LA) ablation or surgery
- •Participants known to require ablation outside the PV region (example, atrioventricular reentrant tachycardia, atrioventricular nodal re-entry tachycardia, atrial tachycardia, ventricular tachycardia and Wolff-Parkinson-White)
- •Previously diagnosed with persistent AF (> 7 days in duration)
- •Severe dilatation of the left atrium (LA) (left anterior descending artery [LAD] >50 millimeter [mm] antero-posterior diameter in case of transthoracic echocardiography [TTE])
- •Presence of LA thrombus
- •Severely compromised left ventricular ejection fraction (left ventricular ejection fraction [LVEF] <40 percentage [%])
- •Uncontrolled heart failure or New York Heart Association (NYHA) Class III or IV
- •History of blood clotting, bleeding abnormalities or contraindication to anticoagulation (heparin, warfarin, or dabigatran)
- •History of a documented thromboembolic event (including transient ischemic attack [TIA]) within the past 6 months
- •Previous percutaneous coronary intervention (PCI) / myocardial infarction (MI) within the past 2 months
- •Previous coronary artery bypass grafting (CABG) in conjunction with valvular surgery, cardiac surgery (example, ventriculotomy, atriotomy) or valvular cardiac (surgical or percutaneous) procedure
- •Unstable angina pectoris within the past 6 months
- •Anticipated cardiac transplantation, cardiac surgery, or other major surgery within the next 12 months
- •Significant pulmonary disease (example, restrictive pulmonary disease, constrictive or chronic obstructive pulmonary disease) or any other disease or malfunction of the lungs or respiratory system that produces severe chronic symptoms
- •Known significant pulmonary vein (PV) anomaly that in the opinion of the investigator would preclude enrollment in this study
- •Prior diagnosis of pulmonary vein stenosis
- •Pre-existing hemi diaphragmatic paralysis
- •Acute illness, active systemic infection, or sepsis
- •Presence of intracardiac thrombus, myxoma, tumor, interatrial baffle or patch or other abnormality that precludes catheter introduction or manipulation
- •Severe mitral regurgitation
- •Presence of implanted pacemaker or implantable cardioverter-defibrillator (ICD) or other implanted metal cardiac device that may interfere with the pulsed electric field energy
- •Presence of a condition that precludes vascular access (such as Inferior Vena Cava [IVC] filter)
- •Significant congenital anomaly or a medical problem that in the opinion of the investigator would preclude enrollment in this study
- •Categorized as vulnerable population and requires special treatment with respect to safeguards of well-being
- •Current enrollment in an investigational study evaluating another device or drug
- •Women who are pregnant (as evidenced by pregnancy test if pre-menopausal), lactating, or who are of child-bearing age and plan on becoming pregnant during the course of the clinical investigation
- •Life expectancy less than 12 months
- •Presenting contra-indications for the devices used in the study, as indicated in the respective Instructions For Use (IFU)
- •Known contraindication for magnetic resonance imaging (MRI) such as use of contrast agents due to advanced renal disease, claustrophobia etcetra. (at principle investigator [PI] discretion)
- •Presence of iron-containing metal fragments in the body
- •Known unresolved pre-existing neurological deficit
- •Known uncontrolled significant gastroesophageal reflux disease (GERD)
结局指标
主要结局
Percentage of Participants with Acute Effectiveness
时间窗: Immediate post-procedure
Percentage of participants with acute effectiveness will be reported. Acute effectiveness is an electrical isolation of clinically relevant targeted pulmonary veins (PVs) (confirmed by entrance block) after adenosine/isoproterenol challenge at the end of the index ablation procedure. Use of a non-study device to achieve PV isolation is considered an acute procedural failure.
Number of Participants with Primary Adverse Events (PAE's)
时间窗: 7 days post-ablation procedure on Day 0 (up to Day 7)
Number of Participants with incidence of PAEs (within 7 days following the ablation procedure) will be reported. PAE's will include the following adverse events atrio-esophageal fistula, phrenic nerve paralysis, cardiac tamponade/perforation, pulmonary vein stenosis, device or procedure related death, stroke/cerebrovascular accident (CVA), major vascular access complication/bleeding, thromboembolism, myocardial infarction, transient ischemic attack (TIA), pericarditis, heart block, pulmonary edema (respiratory insufficiency) and vagal nerve injury/gastroparesis.
次要结局
- 12-month Effectiveness: Number of Participants who Achieved Freedom from Documented Atrial Arrhythmia Episodes During the Effectiveness Evaluation period (AF, AT or AFL of Unknown Origin) within Day 91 to Day 365 Post Index Procedure(Within Day 91 to Day 365 post-ablation procedure (on Day 1))
研究者
研究点 (26)
Loading locations...
相似试验
进行中（未招募）
不适用
A Study of Assessment on Safety and Effectiveness of BWI Pulsed Field Ablation With OMNYPULSE Catheter for the Treatment of Paroxysmal Atrial Fibrillation (PAF)Atrial FibrillationNCT06455098Biosense Webster, Inc.353
招募中
不适用
The effect of pulsed electromagnetic stimulation on the improvement of urinary symptoms in women with urinary incontinenceIRCT201710034582N7rology Research Centre, Guilan University of Medical Sciences100
已完成
不适用
A Study For Treatment Of Paroxysmal Atrial Fibrillation (PAF) With The THERMOCOOL SMARTTOUCH SF Catheter and TRUPULSE GeneratorAtrial FibrillationNCT05752487Biosense Webster, Inc.149
已完成
不适用
Evaluation of the Effectiveness and Safety of the Ulthera™ System for the Treatment of Wrinkles Around the EyesPeriorbital WrinklesNCT00747422Ulthera, Inc100
Unknown
1 期
Safety and Exploratory Efficacy Study of UCMSCs in Patients With Alzheimer's DiseaseAlzheimer's DiseaseNCT02672306South China Research Center for Stem Cell and Regenerative Medicine16